PP
CRSP icon

Peconic Partners’s CRISPR Therapeutics CRSP Stock Holding History

Peconic Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,000
Closed -$1.68M – 43
2021
Q3 		$1.68M Buy
+15,000
New +$1.88M 0.15% 18
2020
Q2 		– Sell
-21,821
Closed -$925K – 62
2020
Q1 		$925K Sell
21,821
-57,704
-73% -$2.98M 0.36% 14
2019
Q4 		$4.84M Sell
79,525
-60,000
-43% -$3.28M 0.99% 17
2019
Q3 		$5.72M Buy
+139,525
New +$6.67M 1.33% 12

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Peconic Partners's CRSP Position: Q4 2021 in Review

Peconic Partners sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 15,000 shares — an estimated $1.68M sold.

Peconic Partners first reported a position in CRSP in Q3 2019 and held it in 4 quarters. The position peaked at $5.72M in Q3 2019. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

  • Peconic Partners reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Peconic Partners sold 15,000 CRISPR Therapeutics shares in Q4 2021, an estimated $1.68M.
  • Peconic Partners first reported a position in CRISPR Therapeutics in Q3 2019 and held it in 4 quarters.
  • Peconic Partners's CRISPR Therapeutics position peaked at $5.72M in Q3 2019.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on Peconic Partners's 13F filing for Q4 2021, filed 14 Feb 2022.